CA-ALORICA
4.3.2024 10:01:32 CET | Business Wire | Press release
Alorica Inc., a global customer experience (CX) leader, announced today the launch of its Real-time Voice Language Translation (ReVoLT), effectively eliminating language barriers during live customer interactions. This offering is the centrepiece of Alorica Clear, an AI-powered solution suite that revolutionises how businesses communicate with their global customer base through seamless voice language translation, accent localisation and background noise cancellation. The services are enabled by an exclusive linguistic processing platform that applies AI to offer translation capabilities designed for multilingual CX across digital and voice channels.
As companies personalise and localise their customer experiences, they face language barriers and cultural nuances that complicate operations and challenge ROI. ReVoLT removes these pain points by providing real-time, bi-directional voice translation in 75 languages. By integrating this technology, organisations can set up their service operations anywhere and support customers across the globe in their native language, improving service and reducing costs by up to 50%.
“The demand for multilingual service is exploding due to an increasingly interconnected world where brands engage consumers through personalised experiences,” stated Mike Clifton, Alorica’s Chief Growth & Transformation Officer. “Customers place high value on localisation, but CX leaders are struggling to efficiently scale their contact centres across multiple geographies. Multilingual support has historically required fragmented queues or locations, which adds complexity and cost while reducing quality. ReVoLT is our strategic response to this growing need, empowering our clients to deliver centralised, effective, and culturally sensitive customer support while achieving significant savings and improved service.”
According to industry data, 29% of businesses cite losing customers because they did not offer multilingual support, and 70% of end users say they feel more loyal to companies that provide services in their native language. Alorica Clear enriches customer interactions and enhances business outcomes through the transformative power of AI, machine translation and large language models.
The Alorica Clear solution suite eliminates friction in global CX delivery through:
- Real-Time Voice Translation – ReVoLT provides bi-directional voice translation, grammar correction and transcription for 75 languages and 200 dialects with high scalability and security.
- Digital Translation – Supporting over 100 languages and dialects, agents can seamlessly deliver multilingual digital transactions via chat, email, and documents.
- Multilingual Cognitive Assistant – Interprets and resolves inquiries digitally in over 100 languages and is uniquely trained to brand voice and objectives.
- Accent Localisation – Mitigates agents' accents during live interactions, adapting to the natural language of the customer to ensure comprehension.
- Noise Cancellation – Eliminates background noise and distractions, tailored to Alorica Anywhere, the company’s work-at-home solution.
“We believe language personalisation is one of the most compelling applications of this exclusive technology, removing longstanding barriers to providing localised service with high quality and efficiency. Real-time voice language translation embodies our commitment to seamless and effective customer experiences, regardless of language differences,” shared Clifton.
Alorica Clear joins the portfolio of technology-infused offerings by Alorica IQ – the company’s digital and innovation practice focused on user experience design, technology solutions and analytics. Experience Alorica Clear’s exclusive Real-Time Voice Language Translation capabilities here.
About Alorica
Alorica creates insanely great digital customer experiences at scale. Our team of 100,000 solutionists, technologists and operators partner with global brands and disruptive innovators to deliver digitally charged, tailored interactions customers crave. With a track record of creating long-term loyalty, Alorica brings actionable insights, proven processes and CX leadership that deliver outcomes critical to clients’ objectives, whether they’re focused on digital optimisation, customer engagement or market expansion. Our digital practice— Alorica IQ—designs, integrates and optimises best-of-breed technology solutions across the customer experience to improve service and increase operational efficiency. Alorica drives CX innovation for the best clients around the globe from its award-winning operations in 19 countries worldwide. To learn more, visit www.alorica.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240304683403/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom